Abstract | BACKGROUND/AIMS: METHODOLOGY: A prospective, controlled study which includes 100 patients with peptic ulcer hemorrhage (male 63, female 37, av.age 57.1 years, SD+/-16, span 26-80; gastric ulcer 50 patients, duodenal ulcer 50 patients) in the period between 1.01.1999 and 15.05.2000 treated in our institution. The bleeding activity was determined according to the Forrest classification. Fifty patients were randomized to receive argon plasma coagulation ( ARCO 2000 ES unit, group A) and in fifty patients injection sclerotherapy (sclerosing with diluted adrenalin 1:10,000 plus polidocanol 1%, group B) was performed. The groups did not differ with respect to age, sex, site, severity of bleeding, use of NSAID and additional diseases. RESULTS: Clinically and endoscopically diagnosed rebleeding occured in 7/50 patients (14%) in group A and in 9/50 patients (18%) in group B; p=0.78. The majority of rebleeding occured within 48 hours after endoscopic hemostasis, group A 4-/7 (57.1%), group B 7/9 (77.7%), p = 0.74. Repeated endoscopic hemostasis did not prove successful in 8 patients (group A 3/50, 6%, group B 5/50, 10%), p=0.71. Seven patients were treated operatively. The total mortality rate was 9% (9/100 patients, group A 4/50, 8%, group B 5/50, 10%), p>0.05. Only one patient died due to peptic ulcer hemorrhage, other 8 patients died due to concomitant diseases. CONCLUSIONS:
|
Authors | Pavel Skok, Igor Krizman, Marija Skok |
Journal | Hepato-gastroenterology
(Hepatogastroenterology)
2004 Jan-Feb
Vol. 51
Issue 55
Pg. 165-70
ISSN: 0172-6390 [Print] Greece |
PMID | 15011856
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Sclerosing Solutions
- Polidocanol
- Polyethylene Glycols
|
Topics |
- Adult
- Aged
- Female
- Hemostasis, Endoscopic
- Humans
- Laser Coagulation
- Male
- Middle Aged
- Peptic Ulcer Hemorrhage
(therapy)
- Polidocanol
- Polyethylene Glycols
(therapeutic use)
- Prospective Studies
- Sclerosing Solutions
(therapeutic use)
- Sclerotherapy
|